Skip to content

Study · Randomized controlled trial · n = 21 · 2026

5 results

Effects of teriparatide on hip structure and bone microarchitecture in women with anorexia nervosa: a placebo-controlled randomized trial.

Amorim T, David NL, Moturi S, Turnquist LR, Holmes TM, Bouxsein ML, Fazeli PK

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA27 Jan 2026

PMID41591404 (opens in a new tab)DOI10.1007/s00198-026-07846-5 (opens in a new tab)PepBankPUB-41591404
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, intertrochanteric buckling ratio decreased 9% from baseline with teriparatide versus a 5% placebo increase (p = 0.076).

    In plain wordsIn women with anorexia nervosa, buckling ratio decreased 9% with teriparatide versus a 5% placebo increase, with no statistically significant difference.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeIntertrochanteric buckling ratio
    Study

    n = 21

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Intertrochanteric buckling ratio decrease from baseline
    9%
    teriparatide
    Intertrochanteric buckling ratio increase
    5%
    placebo

    Source sentences

    Summary
    and IT buckling ratio decreased 9% (vs baseline) in the TPT group (vs a 5% increase in placebo, p = 0.076).
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled study including women with anorexia nervosa and a T-score: ≤ - 2.5.
    Summary · context
    Twenty-one women were randomized to (1) TPT (N = 10; 47.7 ± 8.6yrs) or (2) placebo (N = 11; 47.7 ± 7.7yrs) for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, teriparatide produced no observed changes in bone microarchitecture.

    In plain wordsIn women with anorexia nervosa, bone microarchitecture did not change after teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone microarchitecture
    Study

    n = 10

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After TPT treatment, no changes were observed in bone microarchitecture, but trends in HSA parameters in the intertrochanteric region (IT) of the proximal femur were noted.
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled study including women with anorexia nervosa and a T-score: ≤ - 2.5.
    Summary · context
    Twenty-one women were randomized to (1) TPT (N = 10; 47.7 ± 8.6yrs) or (2) placebo (N = 11; 47.7 ± 7.7yrs) for 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, cortical thickness increased 13% after teriparatide, without statistical significance versus baseline.

    In plain wordsIn women with anorexia nervosa, cortical thickness rose 13% after teriparatide, but the change was not statistically significant.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeIntertrochanteric cortical thickness
    Study

    n = 10

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Intertrochanteric cortical thickness change from baseline
    13%
    teriparatide

    Source sentences

    Summary
    IT cortical thickness increased by 13% (p = 0.075 vs. baseline) after TPT (vs. a non-significant decrease in IT cortical thickness in placebo),
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled study including women with anorexia nervosa and a T-score: ≤ - 2.5.
    Summary · context
    Twenty-one women were randomized to (1) TPT (N = 10; 47.7 ± 8.6yrs) or (2) placebo (N = 11; 47.7 ± 7.7yrs) for 6 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, teriparatide increased circulating osteocalcin by 216.4% versus baseline.

    In plain wordsIn women with anorexia nervosa, teriparatide increased blood osteocalcin by 216.4% compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 10

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Osteocalcin increase from baseline
    216.4%
    teriparatide

    Source sentences

    Summary
    After TPT treatment, circulating levels of osteocalcin and osteopontin increased significantly in TPT (osteocalcin: 216.4%, p = 0.01 vs. baseline and osteopontin: 68.6%, p = 0.03 vs. baseline).
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled study including women with anorexia nervosa and a T-score: ≤ - 2.5.
    Summary · context
    Twenty-one women were randomized to (1) TPT (N = 10; 47.7 ± 8.6yrs) or (2) placebo (N = 11; 47.7 ± 7.7yrs) for 6 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, teriparatide increased circulating osteopontin by 68.6% versus baseline.

    In plain wordsIn women with anorexia nervosa, teriparatide increased blood osteopontin by 68.6% compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteopontin
    Study

    n = 10

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Osteopontin increase from baseline
    68.6%
    teriparatide

    Source sentences

    Summary
    After TPT treatment, circulating levels of osteocalcin and osteopontin increased significantly in TPT (osteocalcin: 216.4%, p = 0.01 vs. baseline and osteopontin: 68.6%, p = 0.03 vs. baseline).
    2 context sentences
    Summary · context
    We conducted a randomized placebo-controlled study including women with anorexia nervosa and a T-score: ≤ - 2.5.
    Summary · context
    Twenty-one women were randomized to (1) TPT (N = 10; 47.7 ± 8.6yrs) or (2) placebo (N = 11; 47.7 ± 7.7yrs) for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.